Platelet Biogenesis is an allogeneic cell therapy company that focuses on platelet biology.
Platelet BioGenesis has raised $75.5M in total funding. The most recent round was Series B. The last funding was announced in November 2021.
Platelet BioGenesis's investors include Qiming Venture Partners, Vivo Capital, Oxford Finance LLC, U.S. Department of War, Massachusetts Life Sciences Center.
Platelet BioGenesis is headquartered in Watertown, United States.
Platelet Biogenesis is an allogeneic cell therapy company that focuses on platelet biology.
Platelet BioGenesis is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Platelet BioGenesis — Funding & Investors." VCBacked, November 4, 2021, https://www.vcbacked.co/company/platelet-biogenesis. Accessed October 31, 2026.
VCBacked. (2021). Platelet BioGenesis — Funding & Investors. Retrieved October 31, 2026, from https://www.vcbacked.co/company/platelet-biogenesis
{{cite web |title=Platelet BioGenesis — Funding & Investors |url=https://www.vcbacked.co/company/platelet-biogenesis |website=VCBacked |access-date=October 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated